CONTACTS 

SUBJECTS
Cetuximab Carboplatin Clinical Study 2nd Arm 7th Cycle 1st Treatment

1003 -
1003 -    ..
1004 - Summary/Objective
1005 -
100501 - Follow up ref SDS J8 0000. ref SDS I9 0000.
100502 -
100503 -
100504 -
100505 -
100506 -
100508 -  ..
1006 -
1007 -
1008 - Progress
1009 -
100901 - Background on Millie's treatment in the clinical study is reported on
100902 - 080508. ref SDS A1 TZ8I
100904 -    ..
100905 -   Taxotere Capecitabine 2nd Relapse IBC Treatment After Mastectomy
100906 -
100907 -   Follow up ref SDS J8 X33O, ref SDS I9 X33O.
100908 -
100909 -   Millie had left mastectomy on 051021.  Biopsy at that time reported
100910 -   no findings of cancer.  Approximately 8 months later on 060707 the
100911 -   doctor diagnosed IBC relapse and prescribed treatment with
100912 -   capecitabine and Taxotere, which had been effective in 2005
100913 -   completely eliminating signs of IBC disease. ref SDS 5 PF3O
100914 -
100915 -    1.  Cycle 09 and 01 ................... 060721, ref SDS 6 407N
100916 -    2.  Cycle 10 and 02 ................... 060814, ref SDS 8 LY6O
100917 -    3.  Cycle 11 and 03 ................... 060908, ref SDS 8 407N
100918 -    4.  Cycle 12 and 04 ................... 060929, ref SDS 8 407N
100919 -    5.  Cycle 13 and 05 ................... 061020, ref SDS 9 407N
100920 -    6.  Cycle 14 and 06 ................... 061110, ref SDS 10 407N
100921 -    7.  Cycle 15 and 07 ................... 061201, ref SDS 11 407N
100923 -    ..
100924 -   Cetuxiab Alone Clinical Study
100925 -
100926 -   Follow up ref SDS J8 356I, ref SDS I9 356I.
100927 -
100928 -   After 7 cycles of treatment in 2006, the doctor diagnosed IBC
100929 -   disease was progressing, and so made referral to UCSF for referral
100930 -   in clinical study of Cetuximab and Carboplatin.  Millie was
100931 -   randominzed for treatment with Cetuximab alone, and began weekly
100932 -   treatments at UCSF on 080201.
100934 -                    ..
100935 -                   Total    Cetuximab
100936 -    8.  Cycle 01 and 08 and 01 01.......... 070201, ref SDS 14 SG8I
100937 -    9.  Cycle 01 and 08 and 02 02.......... 070208, ref SDS 15 SG8I
100938 -   10.  Cycle 01 and 08 and 03 03.......... 070215, ref SDS 16 SG8I
100939 -   11.  Cycle 01 and 08 and 04 04.......... 070222, ref SDS 17 SG8I
100940 -   12.  Cycle 02 and 09 and 01 05.......... 070301, ref SDS 19 SG8I
100941 -   13.  Cycle 02 and 09 and 02 06.......... 070308, ref SDS 21 7T3H
100942 -   14.  Cycle 02 and 09 and 03 07.......... 070315, ref SDS 22 7T3H
100943 -   15.  Cycle 02 and 09 and 04 08.......... 070322, ref SDS 23 7T3H
100944 -   16.  Cycle 03 and 10 and 01 09.......... 070329, ref SDS 24 7T3H
100945 -   17.  Cycle 03 and 10 and 02 10.......... 070405, ref SDS 25 7T3H
100946 -   18.  Cycle 03 and 10 and 03 11.......... 070412, ref SDS 26 7T3H
100947 -   19.  Cycle 03 and 10 and 04 12.......... 070419, ref SDS 27 7T3H
100948 -   20.  Cycle 04 and 11 and 01 13.......... 070426, ref SDS 28 7T3H
100949 -   21.  Cycle 04 and 11 and 02 14.......... 070503, ref SDS 29 7T3H
100950 -   22.  Cycle 04 and 11 and 03 15.......... 070510, ref SDS 30 7T3H
100951 -   23.  Cycle 04 and 11 and 04 16.......... 070517, ref SDS 31 7T3H
100952 -   24.  Cycle 05 and 12 and 01 17.......... 070524, ref SDS 32 7T3H
100953 -   25.  Cycle 05 and 12 and 02 18.......... 070531, ref SDS 33 7T3H
100954 -   26.  Cycle 05 and 12 and 03 19.......... 070607, ref SDS 34 7T3H
100955 -   27.  Cycle 05 and 12 and 04 20.......... 070614, ref SDS 35 0001
100956 -   28.  Cycle 06 and 13 and 01 21.......... 070621, ref SDS 36 0001
100957 -   29.  Cycle 06 and 13 and 02 22.......... 070628, ref SDS 37 0001
100958 -   30.  Cycle 06 and 13 and 03 23.......... 070705, ref SDS 38 0001
100959 -   31.  Cycle 06 and 13 and 04 24.......... 070712, ref SDS 38 0001
100960 -   32.  Cycle 07 and 14 and 01 25.......... 070719, ref SDS 39 0001
100961 -   33.  Cycle 07 and 14 and 02 26.......... 070726, ref SDS 37 0001
100962 -   34.  Cycle 07 and 14 and 03 27.......... 070802, ref SDS 38 0001
100963 -   35.  Cycle 07 and 14 and 04 28.......... 070809, ref SDS 40 0001
100964 -   36.  Cycle 08 and 15 and 01 29.......... 070816, ref SDS 41 0001
100965 -   37.  Cycle 08 and 15 and 02 30.......... 070823, ref SDS 42 0001
100966 -   38.  Cycle 08 and 15 and 03 31.......... 070830, ref SDS 42 0001
100967 -   39.  Cycle 08 and 15 and 04 32.......... 070906, ref SDS 43 0001
100968 -   40.  Cycle 09 and 16 and 01 33.......... 070920, ref SDS 44 0001
100969 -   41.  Cycle 09 and 16 and 02 34.......... 070927, ref SDS 45 0001
100970 -   42.  Cycle 09 and 16 and 03 35.......... 071004, ref SDS 46 0001
100971 -   43.  Cycle 09 and 16 and 04 36.......... 071011, ref SDS 47 0001
100972 -   44.  Cycle 10 and 17 and 01 37.......... 071018, ref SDS 48 0001
100973 -   45.  Cycle 10 and 17 and 02 38.......... 071025, ref SDS 49 0001
100974 -   46.  Cycle 10 and 17 and 03 39.......... 071101, ref SDS 35 0001
100975 -   47.  Cycle 10 and 17 and 04 40.......... 071108, ref SDS 50 0001
100976 -   48.  Cycle 11 and 18 and 01 41.......... 071115, ref SDS 51 0001
100977 -   49.  Cycle 11 and 18 and 02 42.......... 071122, ref SDS 37 0001
100978 -   50.  Cycle 11 and 18 and 03 43.......... 071129, ref SDS 54 0001
100979 -   51.  Cycle 11 and 18 and 04 44.......... 071206, ref SDS 55 0001
100980 -   52.  Cycle 12 and 19 and 01 45.......... 071213, ref SDS 58 0001
100981 -   53.  Cycle 12 and 19 and 02 46.......... 071220, ref SDS 61 0001
100982 -   54.  Cycle 12 and 19 and 03 47.......... 071227, ref SDS 62 0001
100983 -   55.  Cycle 12 and 19 and 04 48.......... 080103, ref SDS 63 0001
100984 -   56.  Cycle 13 and 20 and 01 49.......... 080110, ref SDS 66 0001
100985 -   57.  Cycle 13 and 20 and 02 50.......... 080117, ref SDS 67 0001
100986 -   58.  Cycle 13 and 20 and 03 51.......... 080124, ref SDS 68 0001
100987 -   59.  Cycle 13 and 20 and 04 52.......... 080131, ref SDS 70 0001
100988 -   60.  Cycle 14 and 21 and 01 53.......... 080207, ref SDS 74 0001
100989 -   61.  Cycle 14 and 21 and 02 54.......... 080214, ref SDS 75 0001
100990 -   62.  Cycle 14 and 21 and 03 55.......... 080221, ref SDS 38 0001
100991 -   63.  Cycle 14 and 21 and 04 56.......... 080228, ref SDS 80 0001
100992 -   64.  Cycle 15 and 22 and 01 57 01  00... 080306, ref SDS 83 TZ8I
100994 -    ..
100995 -   Cetuxiab 81 and Carboplatin 14 Treatments Clinical Study 2nd Arm
100996 -
100997 -   Follow up ref SDS J8 5B6J, ref SDS I9 5B6J.
100998 -
100999 -   On 080207 doctor reports IBC may be spreading. ref SDS 73 GH5H
101000 -   Follow up examination on 080219 Doctor Rugo diagnosed progression of
101001 -   disease. ref SDS 95 3J4I  Photographs show spread of IBC rash, UCSF
101002 -   prescribed treatment under the 2nd Arm of the study so that Millie
101003 -   now gets weekly treatment with cetuximab and with Carboplatin 3
101004 -   weeks of each 4 week cycle.
101005 -
101006 -             2nd
101007 -             Arm              Cetuximab Carboplatin
101008 -   65.  Cycle 01 15 and 22 and 02 58 02  01... 080313, ref SDS 85 TZ8I
101009 -   66.  Cycle 01 15 and 22 and 03 59 03  01... 080320, ref SDS 86 TZ8I
101010 -   67.  Cycle 01 15 and 22 and 04 60 04  01... 080327, ref SDS 87 TZ8I
101011 -   68.  Cycle 02 16 and 23 and 01 61 05  02... 080403, ref SDS 88 TZ8I
101012 -   69.  Cycle 02 16 and 23 and 02 62 06  03... 080410, ref SDS 91 TZ8I
101013 -   70.  Cycle 02 16 and 23 and 03 63 07  03... 080417, ref SDS 93 TZ8I
101014 -   71.  Cycle 02 16 and 23 and 04 64 08  03... 080424, ref SDS 96 TZ8I
101015 -   72.  Cycle 03 17 and 24 and 01 65 09  04... 080501, ref SDS 99 5B6J
101016 -   73.  Cycle 03 17 and 24 and 02 66 10  05... 080508, ref SDS A1 5B6J
101017 -   74.  Cycle 03 17 and 24 and 03 67 11  05... 080515, ref SDS A2 5B6J
101018 -   75.  Cycle 03 17 and 24 and 04 68 12  05... 080522, ref SDS A3 5B6J
101019 -   76.  Cycle 04 18 and 25 and 01 69 13  06... 080529, ref SDS A6 5B6J
101020 -   77.  Cycle 04 18 and 25 and 02 70 14  07... 080605, ref SDS A7 5B6J
101021 -   78.  Cycle 04 18 and 25 and 03 71 15  08... 080612, ref SDS B0 5B6J
101022 -   79.  Cycle 04 18 and 25 and 04 72 16  08... 080619, ref SDS B3 5B6J
101023 -   80.  Cycle 05 19 and 26 and 01 73 17  09... 080626, ref SDS B8 5B6J
101024 -   81.  Cycle 05 19 and 26 and 02 74 18  10... 080703, ref SDS C3 5B6J
101025 -   82.  Cycle 05 19 and 26 and 03 75 19  11... 080710, ref SDS C6 5B6J
101026 -   83.  Cycle 05 19 and 26 and 04 76 20  11... 080717, ref SDS D2 5B6J
101027 -   84.  Cycle 06 20 and 27 and 01 77 21  12... 080724, ref SDS D9 5B6J
101028 -   85.  Cycle 06 20 and 27 and 02 78 22  13... 080731, ref SDS E3 5B6J
101029 -   86.  Cycle 06 20 and 27 and 03 79 23  14... 080807, ref SDS E9 5B6J
101030 -   87.  Cycle 06 20 and 27 and 04 80 24  14... 080814, ref SDS F5 5B6J
101031 -   88.  Cycle 07 21 and 28 and 01 81 25  14... 080821, ref SDS F7 5B6J
101032 -   89.  Cycle 07 21 and 28 and 02 82 26  15... 080828, ref SDS G5 5B6J
101033 -   90.  Cycle 07 21 and 28 and 03 83 27  16... 080904, ref SDS G7 5B6J
101034 -   91.  Cycle 07 21 and 28 and 04 84 28  16... 080911, ref SDS G9 5B6J
101035 -   92.  Cycle 08 22 and 29 and 01 85 29  17... 080918, ref SDS H4 5B6J
101036 -   93.  Cycle 08 22 and 29 and 02 86 30  18... 080925, ref SDS H7 5B6J
101037 -   94.  Cycle 08 22 and 29 and 03 87 31  19... 081002, ref SDS H9 5B6J
101038 -   95.  Cycle 08 22 and 29 and 04 88 32  19... 081009, ref SDS I2 5B6J
101039 -   96.  Cycle 09 23 and 28 and 01 89 33  20... 081016, ref SDS I9 5B6J
101040 -   97.  Cycle 09 23 and 28 and 02 90 34  21... 081023, ref SDS J8 5B6J
101042 -  ..
101043 - Treatment on the cetuximab Carboplatin clinical study ended last week
101044 - on 081023 after 90 treatments with cetuximab, and 21 treatments with
101045 - Carboplatin.
101047 -  ..
101048 - On 081016 Doctor Rugo ordered a biopsy to evaluate swelling in the
101049 - left supraclavicular. ref SDS J0 J36R  FNA biopsy was performed on
101050 - 081022 at Kaiser. ref SDS J6 NZ5N  The next day on 081023 Kaiser
101051 - reported pathology on the biopsy was positive for cancer. ref SDS J9
101052 - 4Q9Q  Late in the evening on 081023 Doctor Rugo sent a letter
101053 - notifying that positive results of the biopsy ends Millie's treatment
101054 - in the cetuximab Carboplatin clinical study. ref SDS K0 D65G
101056 -  ..
101057 - Earlier on 080829 the primary crare physician ordered follow on
101058 - treatment for Millie at UCSF after determining progesssion of cancer.
101059 - ref SDS G6 RP8T
101061 -  ..
101062 - On 081016, Doctor Rugo began work implemneting direction from Kaiser
101063 - on 080829 for Millie to start follow on treatment and determined this
101064 - would be in the sunitinib clinical study. ref SDS J0 J34R  At that
101065 - time, UCSF submitted Consent documents for treatment with sunitinib.
101066 - ref SDS J0 J38U  Additionally, on 081016 Doctor Rugo developed a work
101067 - plan for Millie to keep the prior schedule for labs. ref SDS J0 N99W
101069 -  ..
101070 - Review on 081017 of Consent documents for the sunitinib clinical study
101071 - calls for blood work. ref SDS J1 MI7S  On 081031 the study
101072 - coordinator, Glenna, advised that Doctor Rugo wants Millie to get
101073 - another blood draw, as called out in the Consent documents, and in
101074 - place of relying on blood work on 081023. ref SDS K7 XJ87  At that
101075 - time on 081031 Glenna explained the doctor added requirments for
101076 - urinalysis lab work, ref SDS K7 XJ87, which is not discussed in the
101077 - Consent document. ref SDS K7 YP6J
101079 -  ..
101080 - During a call on 081027, Glenna explained the doctor's order for labs
101081 - today. ref SDS K7 ES5O  This order was entered in the UCSF work plan
101082 - for Millie to start treatment in the sunitinib clinical study, shown
101083 - in the record on 081029. ref SDS K6 1H5G, and later confirmed in
101084 - Glenna's letter to Millie on 081031. ref SDS K8 SI4X
101086 -  ..
101087 - Millie met with Glenna this morning in the Breast Care Clinic on the
101088 - 2nd floor.  She signed Consent documents to participate in the
101089 - sunitinib study ordered by Kaiser for Millie's care on 081024.
101090 - ref SDS K3 XZ8W
101092 -  ..
101093 - After meeting with Glenna, Millie went to the Infusion Clinic on the
101094 - 5th floor for lab work ordered in Glenna's letter on 081131.
101095 - ref SDS K8 SI4X
101097 -  ..
101098 - Michelle is Millie's nurse today for the blood draw, and urinalysis
101099 - lab work.
101100 -
101101 -
101102 -
101103 -
101104 -
1012 -

SUBJECTS
Default Null Subject Account for Blank Record

1703 -
170401 -  ..
170402 - Schedule Weekly Treatments Continue on Thursdays
170403 -
170404 - Follow up ref SDS J8 1K7H, ref SDS I9 1K7H.
170406 -  ..
170407 - The schedule for Neupogen is listed on 081018. ref SDS J2 WJ4O
170409 -  ..
170410 - This treatment may no longer be needed for Millie's treatment with the
170411 - sunitinib clinical study, since chemotherapy uses low dose protocol,
170412 - reported in the Consent documents reviewed on 081017. ref SDS J1 SY6F
170414 -  ..
170415 - The current schedule for lab work through 090115 is listed on 080918.
170416 - ref SDS H4 PN6F
170418 -  ..
170419 - Work plan on 081016 to change treatments may affect Millie's schedule
170420 - for labs, since the sunitinib clinical study calls for blood work only
170421 - every 3 weeks, reported on 081017 reviewing the Consent documents.
170422 - ref SDS J1 6R6G
170423 -
170424 -
170425 -
170426 -
170427 -
1705 -

SUBJECTS
Blood Tests Labs Infusion Clinic Evaluate Safe Chemotherapy 1st Trea

2503 -
2504 - 0750
250501 -  ..
250502 - Labs Blood Test
250503 -
250504 - Follow up ref SDS J8 FW5N, ref SDS I9 FW5N.
250505 -
250506 - The sunitinib clincial study requires blood draws every 3 weeks, shown
250507 - in the record on 081017. ref SDS J1 6R6G
250509 -  ..
250510 - Michelle performed the blood draw at 0845 in the Infusion Clinic on
250511 - the 5th floor, as shown in the schedule received on 080918.
250512 - ref SDS H4 1K7H
250514 -  ..
250515 - When Millie went to the Infusion Clinic at Kaiser in Walnut Creek to
250516 - access the Power Port for the CT test at 1300, her nurse, Anne, called
250517 - and requested the report from UCSF to evaluate NEUTS for deciding on
250518 - getting a Neupogen treatment, later in the after the CT test at 1400.
250519 - At that time on 081107 1400, Millie received a copy of the report on
250520 - the labs from Anne in the Infusion Clinic at Kaiser in Walnut Creek.
250521 -
250536 -     ..
250537 -    Log#:                   081107 08:45
250538 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250539 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250540 -     ..
250541 -    CBC with DIFF & PLT CT                                     CBCD
250542 -     ..
250543 -    WBC COUNT               4.1    x10E9/L     3.4  -   10     WBC   WBC x10-3        K/uL     3.4  -  10.0
250544 -    RBC COUNT      L        3.73   x10E12/L      4  -   5.2    RBC   RBC x10-6        M/uL    3.60  -  5.70
250545 -    HEMOGLOBIN             12.6    g/dL         12  -   15.5   HGB   Hemoglobin       g/dL    11.5  -  15.0
250546 -    HEMATOCRIT             35.2    PERCENT      36  -   46     HCT   Hematocrit       %       34.0  -  46.0
250547 -    MCV                    97      fL           80  -   100    MCV   MCV              fL      80.0  -  100.0
250548 -    MCH                    33.8    pg           26  -   34     MCH
250549 -    MCHC                   34.8    g/dL         31  -   36     MCHC
250550 -    PLATELETS             217      x10E9/L     140  -  450     PLT   Plt x10-3        K/uL     140  -  400
250551 -    ..
250552 -     (NEUTS x 1000 = ANC for Kaiser)
250553 -    NEUTS          L        1.67   x10E9/L     1.8  -  6.8     N-A   ANC                      1500
250554 -    Neutrophils    Not Reported                                      Neutrophils       %        50  -  70
250556 -     ..
250557 -    LYMPHS                  1.81   x10E9/L     0.9  -  2.9     L-A   Lymphocytes       %        20  -  50
250558 -    MONOS                   0.26   x10E9/L     0.2  -  0.8     M-A   Monocyte          %         0  -  11
250559 -    EOS                     0.17   x10E9/L     0.0  -  0.4     E-A   Esoinophils       %         1  -  5
250560 -    BASOS                   0.04   x10E9/L     0.0  -  0.1     B-A   Basophil          %         0  -  2
250561 -     ..
250562 -  * LUC/ATYP LYMPHS         0.12   x10E9/L     0.0  -  0.2     LALA
250564 -     ..
250565 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250566 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250567 -    PT            H                s          12.0  -  14.1    PT    PT, patient       sec     8.9  -  11.1
250568 -    INL NRM Ratio H                            0.9  -  1.1     INR   INR                       2.0  -  3.0
250569 -
250570 -        Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250571 -        Francisco, CA  94115
250573 -     ..
250574 -  * PARTIAL
250575 -    THROMBOPLASTIN  H      32.6    s          22.2  - 34.2     INR   PTT
250576 -
250577 -        Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250578 -        Francisco, CA  94115
250580 -     ..
250581 -  * FIBRINOGEN                     mg/dL       202  - 430      FIB
250582 -
250583 -        New test added today, 080818; Catherine says similar to INR.
250585 -     ..
250586 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250587 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250588 -    ELECTROLYTE PANEL                                          LYTE
250589 -    SODIUM         L      137      mmol/L      134  -  143     NA    Sodium            mEq/L   137  -  145
250590 -    POTASSIUM               4.0    mmol/L      3.4  -  4.9     K     Potassium         mEq/L   3.5  -  5.3
250591 -    CHLORIDE              104      mmol/L       98  -  107     CL
250592 -    CARBON DIOX TOTAL      23      mmol/L       23  -  32      CO2
250593 -    ANION GAP              10                    3  -  14      ANGA
250594 -     ..
250595 - *  UREA NITROGEN          11      mg/dL         8  -  23      BUN   BUN               mg/dL     7  -  17
250596 -    GLUCOSE                        mg/dL        70  -  199     GLU   Glucose           mg/dL     ?  -   ?
250597 -    AST            H       48      U/L          16  -  41      AST   AST (SGOT)        U/L      14  -  36
250598 -    ALT                    35      U/L          11  -  54      ALT   ALT (SGPT)        U/L      11  -  66
250599 -    BILIRUBIN, TOTAL        1.3    mg/dL       0.3  - 1.3      BILT  Bili Total        mg/dL   0.2  - 1.3
250600 -    ALKALINE PHOSPHATASE   78      U/L          29  - 111      ALKP  Alkaline Ph       U/L      38  - 126
250601 -     ..
250602 -    PROTEIN, TOTAL                 g/dL        5.8  - 8.0      TP    Protine Total     g/dL    6.3  - 8.2
250603 -    ALBUMIN                        g/dL        3.4  - 4.7      ALB   Albumin           g/dL    3.4  - 4.8
250604 -    CALCIUM                        mg/dL       8.7  - 10.1     CA    Calcium           mg/dL   8.4  - 10.2
250605 -     ..
250606 -    MAGNESIUM                      mg/dL       1.8  -  2.3     MG    Magnesium         mg/dL   1.6  -  2.3
250608 -     ..
250609 -    CREAT with eGFR
250610 -    CREATININE              0.41   mg/dL      0.42  - 1.06     CR    Creatinine        mg/dL   0.6  -  1.2
250611 -
250612 -      Note: Creatinine assay changed to IDMS standardization on
250613 -      February 4, 2008 causing decrease in results of approximately
250614 -      0.09 mg/dL
250616 -     ..
250617 -    eGFR if Caucasian     >60      mL/min                      GFRC
250618 -    eGFR if African Amer  >60      mL/min                      GFRA
250619 -
250620 -      eGFR corrected for 1.73 sq meters of body surface area
250621 -      Note:  eGFR is only an estimation. Please see online Lab Manual
250622 -      for potential limitations.
250623 -      Performed at Mt Zion Clin Lab, 1600 Divisadero, San Francisco,
250624 -      CA  94115
250626 -     ..
250627 -    <----------------------- U C S F -----------------------> <-------------  Kaiser -------------->
250628 -    Type                 Results   Units        Normal        ACRO   Type            Units        Normal
250629 -    URINALYSIS, ROUTINE                                        LYTE
250630 -    GLUCOSE                  NEG   mg/dL          NEG          GLUA
250631 -    BILIRUBIN                NEG                  NEG          BIUA
250632 -    KEYTONES                 NEG   mg/dL          NEG          KEUA
250633 -    SPECIFIC GRAVITY     <= 1.005              1.02 - 1.030    SGU
250634 -    HEMOGLOBIN              Trace                 NEG          HBUA
250635 -    PH                      5.5                4.5  - 5.0      PHUA
250636 -    PROTEIN                  NEG   mg/dL          NEG          PRUA
250637 -    NITRITE                  NEG                  NEG          NIUA
250638 -    WBC ESTERASE  ,UR        NEG                  NEG          WBCE
250639 -
250640 -        Performed at Mt Zion Clinic Lab, 1600 Divisadero, San
250641 -        Francisco, CA  94115
250642 -
250644 -     ..
250645 - *  Labs today 081023 included tests omitted on 081016 labs...
250646 -
250647 -            LUC/ATYP LYMPHS...................... ref SDS I9 Z47G
250649 -     ..
250650 -    Labs today 081023 omitted tests included on 081016 labs...
250651 -
250652 -            PARTIAL THROMBOPLASTIN............... ref SDS J8 GQ6F
250654 -     ..
250655 -    Labs included on 081016 tests omitted on 080918 labs...
250656 -
250657 -            LUC/ATYP LYMPHS...................... ref SDS I9 Z47G
250659 -     ..
250660 -    Labs omitted tests on 081016 included on 080918 labs...
250661 -
250662 -            PARTIAL THROMBOPLASTIN............... ref SDS H4 GQ6F
250663 -            FIBRINOGEN........................... ref SDS H4 VE6I
250665 -     ..
250666 -    Labs on 080821 omitted following tests...
250667 -
250668 -            GLUCOSE.............................. ref SDS F7 SE9J
250669 -            ALBUMIN.............................. ref SDS F7 GT9I
250670 -            PROTEIN, TOTAL
250672 -     ..
250673 -    Labs on 080726 omitted following tests...
250674 -
250675 -            GLUCOSE.............................. ref SDS D9 SE9J
250676 -            ALBUMIN.............................. ref SDS D9 GT9I
250678 -     ..
250679 -    Labs on 080626 omitted following tests...
250680 -
250681 -            GLUCOSE.............................. ref SDS B8 HS7I
250682 -            PROTEIN, TOTAL
250683 -            ALBUMIN
250684 -            CALCIUM
250686 -  ..
250687 - Case study on 080626 shows these four tests, which have been omitted
250688 - and included in various combinations the past 4 cycles, were
250689 - consistently included for the prevous 15 cycles. ref SDS B8 HS8F
250690 -
250691 -
250692 -
2507 -

SUBJECTS
Default Null Subject Account for Blank Record

2603 -
260401 -  ..
260402 - Cancer Marker CA 15-3 95 Stable for 8 Weeks Remarkable Unusual
260403 -
260404 - Follow up ref SDS J8 VK6H, ref SDS I9 VK6H.
260405 -
260406 - Cancer marker was not drawn today, because Millie does not start
260407 - treatment until next week on 081113, and next week is the regular
260408 - schedule for drawing the cance marker on a 4 week schedule, since the
260409 - last test was on 081016. ref SDS J8 VK6H
260410 -
260411 -
260412 -
2605 -

SUBJECTS
Absolute Neutrophils Count ANC 6850 Above 1500 NEUTS 6.85 Above 1.5

3503 -
350401 -  ..
350402 - NEUTS 1.67 Increase Minimally after 2 Weeks without Cheotherapy
350403 - Blood Counts Rise Less than Expected No Chemotherapy for 2 Weeks
350404 -
350405 - Follow up ref SDS J8 PU6K, ref SDS I9 PU6K.
350406 -
350407 - Blood counts increased minimally from the prior test on 081023, shown
350408 - by the Lab report today with NEUTS 1.65, ref SDS 0 QY6H, compared with
350409 - NEUTS 1.65 2 weeks ago on 081023, ref SDS J8 QY6H  This is above UCSF
350410 - standard of 1.5 for Millie to safely get chemotherapy treatment.
350412 -  ..
350413 - Since Millie has not had treatment for several weeks, and had 2
350414 - Neupogen treatments on 081026, ref SDS K5 UZ7K, blood counts would be
350415 - expected to be much higher.
350417 -  ..
350418 - Neutropenia causes a "roller coaster" above and below specified target
350419 - from week to week, while getting Neupogen treatments in recent months,
350420 - is shown in case study below. ref SDS J8 OK67
350422 -  ..
350423 - Patient history getting cetuximab and Carboplatin is listed above.
350424 - ref SDS I9 5B6J  The doctor stopped this treatment due to progression
350425 - of disease on 081023. ref SDS K0 D65G
350427 -  ..
350428 - Side effects of Neupogen are listed below. ref SDS I9 SB8I
350430 -  ..
350431 - Fitness from hiking is listed in case study on 081021. ref SDS J5 8G5M
350432 -
350433 -
350434 -
350435 -
3505 -

SUBJECTS
Default Null Subject Account for Blank Record

3603 -
360401 -  ..
360402 - Neupogen Case Study Missed Carboplatin Treatments Low Blood Counts
360403 -
360404 - Follow up ref SDS J8 EP7N, ref SDS I9 EP7N.
360405 -
360406 - Case study on 060809 shows Millie has often received chemotherapy when
360407 - blood counts are below the standard for safe treatments, and on some
360408 - occassions has received Neupogen to increase blood counts. ref SDS 7
360409 - HV45
360411 -  ..
360412 - Research on neutropenia was reported on 070301, ref SDS 18 O59H, when
360413 - Doctor Rugo was concerned about holding blood counts with weekly
360414 - Carboplatin treatments. ref SDS 18 VF6O
360416 -  ..
360417 - With 2 treatments scheduled for this week, Millie will have received
360418 - 44 Neupogen treatments, and missed 4 chemotherapy treatments due to
360419 - rising neutropenia, shown in case study today on patient history.
360420 - ref SDS 0 V19M  She last missed Carboplatin treatment on 080821.
360421 - ref SDS F7 PU6K
360423 -  ..
360424 - Millie's letter to the medical team on 080307 asked about solving low
360425 - blood counts. ref SDS 84 HS6R  On 080423 Millie notified the medical
360426 - team to maintain a full dose of Carboplatin because these treatments
360427 - yielded favorable response. ref SDS 94 TY6Y  On 080501 a mixup in
360428 - communication reduced the dose of Carboplatin with the aim of not
360429 - missing treatments.  Adding Neupogen to avoid missing treatments might
360430 - have enabled maintaining full dose of Carboplatin to increase
360431 - recovery. ref SDS 98 CZ3N
360433 -  ..
360434 - Fitness from hiking is listed in case study on 081021. ref SDS J5 8G5M
360436 -  ..
360437 - Reduced treatment may relate to rising cancer marker CA 15-3 96 on
360438 - 080821. ref SDS F7 A16M  Millie has received only 17 of 21 total
360439 - treatments prescribed with Carboplatin, since starting the 2nd arm of
360440 - the clinical study on 080306...
360442 -        ..
360443 -                      Neupogen            Carboplatin
360444 -       Date    NEUTS  Cur Totl Cycl Trm  Rcvd   Missed
360445 -
360446 -        081107  1.67   2   44    9   2    21.......... ref SDS 0 QY6H
360447 -        081023  1.65   2   42    9   2    21.......... ref SDS J8 QY6H
360448 -        081016  2.55   2   40    9   1    20.......... ref SDS I9 QY6H
360449 -        081009  1.98   2   38    8   4    19.......... ref SDS I2 QY6H
360450 -        081002  1.93   2   36    8   3    19.......... ref SDS H9 QY6H
360451 -        080925  3.82   2   34    8   2    18.......... ref SDS H7 QY6H
360452 -        080918  2.07   2   32    8   1    17.......... ref SDS H4 QY6H
360453 -        080911  1.43   2   30    7   4    16.......... ref SDS G9 QY6H
360454 -        080904  1.99   2   28    7   3    16.......... ref SDS G7 QY6H
360455 -        080828  3.09   2   26    7   2    15.......... ref SDS G5 QY6H
360456 -        080821  0.99   2   24    7   1    14      4... ref SDS F7 QY6H
360457 -        080814  1.37   0   22    6   4    14.......... ref SDS F5 QY6H
360458 -        080807  2.41   2   22    6   3    14.......... ref SDS E9 QY6H
360459 -        080731  1.92   2   20    6   2    13.......... ref SDS E3 QY6H
360460 -        080724  2.32   2   18    6   1    12.......... ref SDS D9 QY6H
360461 -        080717  2.47   1   16    5   4    11.......... ref SDS D2 QY6H
360462 -        080710  5.12   2   15    5   3    11.......... ref SDS C6 QY6H
360463 -        080703  2.90   2   13    5   2    10.......... ref SDS C3 QY6H
360464 -        080626  1.80   2   11    5   1    09.......... ref SDS B8 QY6H
360465 -        080619  0.74   1    9    4   4    08.......... ref SDS B3 QY6H
360466 -        080612  3.77   2    8    4   3    08.......... ref SDS B0 QY6H
360467 -        080605  1.55   2    6    4   2    07.......... ref SDS A7 QY6H
360468 -        080529  2.26   1    4    4   1    06.......... ref SDS A6 QY6H
360469 -        080522  0.96   0         3   4    05.......... ref SDS A3 QY6H
360470 -        080515  1.21   0         3   3    05      3... ref SDS A2 QY6H
360471 -        080508  5.41   1    3    3   2    05.......... ref SDS A1 QY6H
360472 -        080501  1.34   1    2    3   1    04.......... ref SDS 99 QY6H
360473 -        080424  1.34   0         2   4    03.......... ref SDS 96 QY6H
360474 -         ..
360475 -        080417  0.95   0         2   3    03      2... ref SDS 93 QY6H
360476 -        080410  6.85   0         2   2    03.......... ref SDS 91 QY6H
360477 -        080403  1.34   1    1    2   1    02.......... ref SDS 88 QY6H
360478 -        080327  2.30   0         1   4    01.......... ref SDS 87 QY6H
360479 -        080320  1.28   0         1   3    01      1... ref SDS 86 QY6H
360480 -        080313  2.05   0         1   2    01.......... ref SDS 85 QY6H
360481 -        080306  1.75   0         1   1    00.......... ref SDS 83 QY6H
360482 -
360483 -
3605 -

SUBJECTS
Default Null Subject Account for Blank Record

3703 -
370401 -  ..
370402 - Side Effects Neupogen Treatments Continue Mild Tolerance Acceptable
370403 -
370404 - Follow up ref SDS J8 SB8I, ref SDS I9 SB8I.
370405 -
370406 - Fitness from hiking is listed in case study on 081021. ref SDS J5 8G5M
370408 -  ..
370409 - Millie last reported side effects on 081011 experiencing bone pain,
370410 - headache, and fatigue associated with Neupogen and chemotherapy.
370411 - ref SDS I4 FL4H
370413 -  ..
370414 - Side effects of Neupogen may be lessening, reported on...
370415 -
370416 -               081011................, ref SDS I4 FL4H
370417 -               081010................, ref SDS I3 SB8I
370418 -               081006................, ref SDS I1 3E4K
370419 -               081004................, ref SDS I0 Y17L
370420 -               081002................, ref SDS H9 Y17L
370421 -               080930................, ref SDS H8 Y17L
370422 -               080923................, ref SDS H6 K16F
370423 -               080915................, ref SDS H1 9W9I
370424 -               080810................, ref SDS F3 9W9I
370425 -               080803................, ref SDS E4 9W9I
370426 -               080726................, ref SDS E1 9W9I
370427 -               080721................, ref SDS D6 9W9I
370428 -               080713................, ref SDS C9 RM94
370429 -               080629................, ref SDS C2 6Q5J
370430 -               080628................, ref SDS C0 6Q5J
370431 -
370432 -
370433 -
370434 -
370435 -
3705 -

SUBJECTS
Default Null Subject Account for Blank Record

5203 -
520401 -  ..
520402 - Coagulation Control INR 2.3 Within Range Treating Pulmonary Embolism
520403 -
520404 - Follow up ref SDS J8 K66J, ref SDS I9 K66J.
520405 -
520406 - INR was not drawn today for reasons discussed for the cancer marker,
520407 - shown above. ref SDS 0 VK6H
520408 -
520409 -
520410 -
520411 -
520412 -
520413 -
520414 -
520415 -
5205 -